Daunorubicin

DB00694

small molecule approved

Deskripsi

A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms.

Struktur Molekul 2D

Berat 527.5199
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) Daunorubicin has been determined to have a terminal half-life of 18.5 h (+/- 4.9).[A237395] Daunorubicinol, the primary active metabolite has been determined to have a terminal half-life of 26.7 h (+/- 12.8). The mean half-life of elimination of liposomal daunorubicin has been reported to be 22.1 h in pharmacokinetic studies and 31.5 h in official FDA labeling.[A237405 ,L32843]
Volume Distribusi Daunorubicin has a steady-state volume of distribution of 1.91 L/m<sup>2</sup> reported with the liposomal formulation.[A237395] The average volume of distribution reported for the liposomal formulation is 6.6 L. [L32843]
Klirens (Clearance) Daunorubicin has a clearance of 68.4 mL/h/m<sup>2</sup> determined using the liposomal formulation.[A237405]

Absorpsi

Daunorubicin was found to have a tmax of 2 h and a cmax of 24.8 ?g/mL after a 90 min infusion of the liposomal formulation at a dose of 44 mg/m2. A237405

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Daunorubicin is eliminated hepatically. 40% of daunorubicin is excreted in the bile while 25% is excreted in an active form (daunorubicin or daunorubicinol) in the urine.L35460 In the liposomal formulation, only 9% of active molecules are excreted in the urine.L32843

Farmakogenomik

7 Varian
CYP1B1 (rs10932125)

The presence of this genotype in CYP1B1 may be associated with an increased risk of drug-induced cytotoxicity from daunorubicin therapy.

HNRNPD (rs3750518)

The presence of this genotype in HNRNPD may be associated with an increased risk of drug-induced cytotoxicity from daunorubicin therapy.

SEC14L3 (rs6603859)

The presence of this genotype in SEC14L3 may be associated with an increased risk of drug-induced cytotoxicity from daunorubicin therapy.

IKBKE (rs7929521)

The presence of this genotype in IKBKE may be associated with an increased risk of drug-induced cytotoxicity from daunorubicin therapy.

RARG (rs2229774)

Pediatric patients who carry this genotype may be at a higher risk of experiencing anthracycline-induced cardiotoxicity when treated with daunorubicin.

SLC28A3 (rs7853758)

Pediatric patients who carry this genotype may be at a higher risk of experiencing anthracycline-induced cardiotoxicity when treated with daunorubicin.

UGT1A6 (rs17863783)

Pediatric patients who carry this genotype may be at a higher risk of experiencing anthracycline-induced cardiotoxicity when treated with daunorubicin.

Interaksi Obat

857 Data
Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Daunorubicin.
Peginterferon alfa-2a The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Daunorubicin.
Interferon alfa-n1 The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Daunorubicin.
Interferon alfa-n3 The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Daunorubicin.
Peginterferon alfa-2b The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Daunorubicin.
Interferon gamma-1b The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Daunorubicin.
Interferon alfa-2a The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Daunorubicin.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Daunorubicin.
Pegaspargase The risk or severity of adverse effects can be increased when Pegaspargase is combined with Daunorubicin.
Interferon beta-1b The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Daunorubicin.
Interferon alfacon-1 The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Daunorubicin.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Daunorubicin.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Daunorubicin.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Daunorubicin.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Daunorubicin.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Daunorubicin.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Daunorubicin.
Alefacept The risk or severity of adverse effects can be increased when Alefacept is combined with Daunorubicin.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Daunorubicin.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Daunorubicin.
Interferon alfa-2b The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Daunorubicin.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Daunorubicin.
Phenylalanine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Daunorubicin.
Cladribine Daunorubicin may increase the immunosuppressive activities of Cladribine.
Carmustine The risk or severity of adverse effects can be increased when Carmustine is combined with Daunorubicin.
Amsacrine The risk or severity of adverse effects can be increased when Amsacrine is combined with Daunorubicin.
Bleomycin The risk or severity of adverse effects can be increased when Bleomycin is combined with Daunorubicin.
Chlorambucil The risk or severity of adverse effects can be increased when Chlorambucil is combined with Daunorubicin.
Raltitrexed The risk or severity of adverse effects can be increased when Raltitrexed is combined with Daunorubicin.
Mitomycin The risk or severity of adverse effects can be increased when Mitomycin is combined with Daunorubicin.
Floxuridine The risk or severity of adverse effects can be increased when Floxuridine is combined with Daunorubicin.
Indomethacin The risk or severity of adverse effects can be increased when Indomethacin is combined with Daunorubicin.
Tioguanine The risk or severity of adverse effects can be increased when Tioguanine is combined with Daunorubicin.
Dexrazoxane The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Daunorubicin.
Streptozocin The risk or severity of adverse effects can be increased when Streptozocin is combined with Daunorubicin.
Trifluridine The risk or severity of adverse effects can be increased when Trifluridine is combined with Daunorubicin.
Gemcitabine The risk or severity of adverse effects can be increased when Gemcitabine is combined with Daunorubicin.
Epirubicin The risk or severity of adverse effects can be increased when Epirubicin is combined with Daunorubicin.
Lenalidomide The risk or severity of adverse effects can be increased when Lenalidomide is combined with Daunorubicin.
Altretamine The risk or severity of adverse effects can be increased when Altretamine is combined with Daunorubicin.
Zidovudine The risk or severity of adverse effects can be increased when Zidovudine is combined with Daunorubicin.
Cisplatin The risk or severity of adverse effects can be increased when Cisplatin is combined with Daunorubicin.
Oxaliplatin The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Daunorubicin.
Fluorouracil The risk or severity of adverse effects can be increased when Fluorouracil is combined with Daunorubicin.
Propylthiouracil The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Daunorubicin.
Pentostatin The risk or severity of adverse effects can be increased when Pentostatin is combined with Daunorubicin.
Linezolid The risk or severity of adverse effects can be increased when Linezolid is combined with Daunorubicin.
Clofarabine The risk or severity of adverse effects can be increased when Clofarabine is combined with Daunorubicin.
Prednisone The risk or severity of adverse effects can be increased when Prednisone is combined with Daunorubicin.
Pemetrexed The risk or severity of adverse effects can be increased when Pemetrexed is combined with Daunorubicin.
Fludrocortisone The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Daunorubicin.
Mycophenolate mofetil The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Daunorubicin.
Tretinoin The risk or severity of cardiotoxicity can be increased when Daunorubicin is combined with Tretinoin.
Sulfasalazine The risk or severity of adverse effects can be increased when Daunorubicin is combined with Sulfasalazine.
Dacarbazine The risk or severity of adverse effects can be increased when Daunorubicin is combined with Dacarbazine.
Temozolomide The risk or severity of adverse effects can be increased when Daunorubicin is combined with Temozolomide.
Penicillamine The risk or severity of adverse effects can be increased when Daunorubicin is combined with Penicillamine.
Mechlorethamine The risk or severity of adverse effects can be increased when Daunorubicin is combined with Mechlorethamine.
Azacitidine The risk or severity of adverse effects can be increased when Daunorubicin is combined with Azacitidine.
Carboplatin The risk or severity of adverse effects can be increased when Daunorubicin is combined with Carboplatin.
Dactinomycin The risk or severity of adverse effects can be increased when Daunorubicin is combined with Dactinomycin.
Azathioprine The risk or severity of adverse effects can be increased when Daunorubicin is combined with Azathioprine.
Hydroxyurea The risk or severity of adverse effects can be increased when Daunorubicin is combined with Hydroxyurea.
Mycophenolic acid The risk or severity of adverse effects can be increased when Daunorubicin is combined with Mycophenolic acid.
Mercaptopurine The risk or severity of adverse effects can be increased when Daunorubicin is combined with Mercaptopurine.
Thalidomide The risk or severity of adverse effects can be increased when Daunorubicin is combined with Thalidomide.
Melphalan The risk or severity of adverse effects can be increased when Daunorubicin is combined with Melphalan.
Fludarabine The risk or severity of adverse effects can be increased when Daunorubicin is combined with Fludarabine.
Flucytosine The risk or severity of adverse effects can be increased when Daunorubicin is combined with Flucytosine.
Capecitabine The risk or severity of adverse effects can be increased when Daunorubicin is combined with Capecitabine.
Procarbazine The risk or severity of adverse effects can be increased when Daunorubicin is combined with Procarbazine.
Arsenic trioxide The risk or severity of adverse effects can be increased when Daunorubicin is combined with Arsenic trioxide.
Idarubicin The risk or severity of adverse effects can be increased when Daunorubicin is combined with Idarubicin.
Estramustine The risk or severity of adverse effects can be increased when Daunorubicin is combined with Estramustine.
Lomustine The risk or severity of adverse effects can be increased when Daunorubicin is combined with Lomustine.
Eculizumab The risk or severity of adverse effects can be increased when Daunorubicin is combined with Eculizumab.
Decitabine The risk or severity of adverse effects can be increased when Daunorubicin is combined with Decitabine.
Nelarabine The risk or severity of adverse effects can be increased when Daunorubicin is combined with Nelarabine.
Ciclesonide The risk or severity of adverse effects can be increased when Daunorubicin is combined with Ciclesonide.
Stepronin The risk or severity of adverse effects can be increased when Daunorubicin is combined with Stepronin.
Hydroxychloroquine The risk or severity of adverse effects can be increased when Daunorubicin is combined with Hydroxychloroquine.
Castanospermine The risk or severity of adverse effects can be increased when Daunorubicin is combined with Castanospermine.
Vorinostat The risk or severity of adverse effects can be increased when Daunorubicin is combined with Vorinostat.
2-Methoxyethanol The risk or severity of adverse effects can be increased when Daunorubicin is combined with 2-Methoxyethanol.
Brequinar The risk or severity of adverse effects can be increased when Daunorubicin is combined with Brequinar.
Aldosterone The risk or severity of adverse effects can be increased when Daunorubicin is combined with Aldosterone.
Pirfenidone The risk or severity of adverse effects can be increased when Daunorubicin is combined with Pirfenidone.
Interferon alfa The risk or severity of adverse effects can be increased when Daunorubicin is combined with Interferon alfa.
Glatiramer The risk or severity of adverse effects can be increased when Daunorubicin is combined with Glatiramer.
Briakinumab The risk or severity of adverse effects can be increased when Daunorubicin is combined with Briakinumab.
Human interferon omega-1 The risk or severity of adverse effects can be increased when Daunorubicin is combined with Human interferon omega-1.
Mepolizumab The risk or severity of adverse effects can be increased when Daunorubicin is combined with Mepolizumab.
Abetimus The risk or severity of adverse effects can be increased when Daunorubicin is combined with Abetimus.
Belatacept The risk or severity of adverse effects can be increased when Daunorubicin is combined with Belatacept.
Bendamustine The risk or severity of adverse effects can be increased when Daunorubicin is combined with Bendamustine.
Pralatrexate The risk or severity of adverse effects can be increased when Daunorubicin is combined with Pralatrexate.
Wortmannin The risk or severity of adverse effects can be increased when Daunorubicin is combined with Wortmannin.
Eribulin The risk or severity of adverse effects can be increased when Daunorubicin is combined with Eribulin.
Belimumab The risk or severity of adverse effects can be increased when Daunorubicin is combined with Belimumab.
Teriflunomide The risk or severity of adverse effects can be increased when Daunorubicin is combined with Teriflunomide.

Target Protein

DNA
DNA topoisomerase 2-alpha TOP2A
DNA topoisomerase 2-beta TOP2B

Referensi & Sumber

Synthesis reference: Sylvie Pinnert, Leon Ninet, Jean Preud'Homme, "Antibiotic daunorubicin and its preparation." U.S. Patent US3989598, issued March, 1965.
Artikel (PubMed)
  • PMID: 6189661
    Balis FM, Holcenberg JS, Bleyer WA: Clinical pharmacokinetics of commonly used anticancer drugs. Clin Pharmacokinet. 1983 May-Jun;8(3):202-32. doi: 10.2165/00003088-198308030-00002.
  • PMID: 32955826
    Cafaro A, Giannini MB, Silimbani P, Cangini D, Masini C, Ghelli Luserna Di Rora A, Simonetti G, Martinelli G, Cerchione C: CPX-351 daunorubicin-cytarabine liposome: a novel formulation to treat patients with newly diagnosed secondary acute myeloid leukemia. Minerva Med. 2020 Oct;111(5):455-466. doi: 10.23736/S0026-4806.20.07017-2. Epub 2020 Sep 21.
  • PMID: 31213803
    Mayer LD, Tardi P, Louie AC: CPX-351: a nanoscale liposomal co-formulation of daunorubicin and cytarabine with unique biodistribution and tumor cell uptake properties. Int J Nanomedicine. 2019 May 23;14:3819-3830. doi: 10.2147/IJN.S139450. eCollection 2019.
  • PMID: 32644499
    Saleem T, Kasi A: Daunorubicin .

Contoh Produk & Brand

Produk: 24 • International brands: 6
Produk
  • Cerubidine
    Injection, powder, for solution • 20 mg/4mL • Intravenous • US • Generic • Approved
  • Cerubidine
    Powder, for solution • 20 mg / vial • Intravenous • Canada • Approved
  • Daunorubicin Hydrochloride
    Injection • 5 mg/1mL • Intravenous • US • Generic • Approved
  • Daunorubicin Hydrochloride
    Injection, solution • 5 mg/1mL • Intravenous • US • Generic • Approved
  • Daunorubicin Hydrochloride
    Injection, powder, lyophilized, for solution • 5 mg/1mL • Intravenous • US • Generic • Approved
  • Daunorubicin Hydrochloride
    Injection, powder, for solution • 20 mg/1 • Intravenous • US
  • Daunorubicin Hydrochloride
    Injection • 5 mg/1mL • Intravenous • US • Approved
  • Daunorubicin Hydrochloride
    Injection • 5 mg/1mL • Intravenous • US • Approved
Menampilkan 8 dari 24 produk.
International Brands
  • Cerubidin — Sanofi-Aventis
  • Cérubidine — Sanofi-Aventis
  • Daunoblastin — Pfizer
  • Daunoblastina — Pfizer
  • Daunorrubicina — GP-Pharm
  • Maxidauno — Varifarma

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul